Clinical Trials Logo
  1. Home
  2. Primary IgA Nephropathy
  3. NCT05847920

Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy

Primary IgA Nephropathy Clinical Trial

Official title:
A Phase II Seamless Design, Randomized, Double-blind, Placebo-controlled, Dose-exploration Study Evaluate the Efficacy and Safety of SHR-2010 Injection in Patients With Primary IgA Nephropathy

Clinical Trial Summary

The study is being conducted to evaluate the efficacy, and safety of SHR - 2010 injection in patients with primary IgA nephropathy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05847920
Study type Interventional
Source Guangdong Hengrui Pharmaceutical Co., Ltd
Contact Fei Gu
Phone 17721288037
Email fei.gu@hengrui.com
Status Recruiting
Phase Phase 2
Start date June 4, 2023
Completion date April 30, 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT03643965 - Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy Phase 3
Recruiting NCT04557462 - A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy Phase 3
Active, not recruiting NCT04541043 - Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE) Phase 3
Recruiting NCT02765594 - Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy Phase 4
Not yet recruiting NCT02712697 - Integrative Medicine of IgA Nephropathy N/A
Completed NCT04887532 - A Trial of HR19042 Capsule in Healthy Chinese Subjects Phase 1
Not yet recruiting NCT06137768 - A Trial of HRS-5965 Tablets in Primary IgA Nephropathy Phase 2
Completed NCT02351752 - Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study Phase 4
Active, not recruiting NCT04014335 - A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy Phase 2
Completed NCT01738035 - The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease Phase 2
Recruiting NCT05797610 - A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression Phase 3